PT3302454T - Composições para utilização no tratamento da doença de parkinson e distúrbios associados - Google Patents

Composições para utilização no tratamento da doença de parkinson e distúrbios associados

Info

Publication number
PT3302454T
PT3302454T PT167344811T PT16734481T PT3302454T PT 3302454 T PT3302454 T PT 3302454T PT 167344811 T PT167344811 T PT 167344811T PT 16734481 T PT16734481 T PT 16734481T PT 3302454 T PT3302454 T PT 3302454T
Authority
PT
Portugal
Prior art keywords
disease
compositions
related disorders
treating parkinson
parkinson
Prior art date
Application number
PT167344811T
Other languages
English (en)
Original Assignee
Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Lusomedicamenta S A
LABORATORIO MEDINFAR PRODUTOS FARMACAªUTICOS S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investig E Desenvolvimento Em Biotecnologia Sa, Lusomedicamenta S A, LABORATORIO MEDINFAR PRODUTOS FARMACAªUTICOS S A filed Critical Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Publication of PT3302454T publication Critical patent/PT3302454T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT167344811T 2015-05-26 2016-05-25 Composições para utilização no tratamento da doença de parkinson e distúrbios associados PT3302454T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562166531P 2015-05-26 2015-05-26

Publications (1)

Publication Number Publication Date
PT3302454T true PT3302454T (pt) 2021-04-01

Family

ID=56322267

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167344811T PT3302454T (pt) 2015-05-26 2016-05-25 Composições para utilização no tratamento da doença de parkinson e distúrbios associados

Country Status (9)

Country Link
US (1) US10471025B2 (pt)
EP (1) EP3302454B1 (pt)
JP (1) JP6853791B2 (pt)
CN (1) CN107660147B (pt)
AU (1) AU2016266432B2 (pt)
CA (1) CA2986891C (pt)
ES (1) ES2869981T3 (pt)
PT (1) PT3302454T (pt)
WO (1) WO2016190766A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282120B2 (en) * 2018-10-11 2025-08-01 Indivior Uk Ltd Buprenorphine to treat respiratory depression
WO2020139797A1 (en) * 2018-12-24 2020-07-02 Sorrento Therapeutics, Inc. Methods for treating parkinson's disease by administering resiniferatoxin
TW202233169A (zh) * 2020-11-10 2022-09-01 瑞典商瑞典綜合研究實驗室公司 包含[2-(3-氟-5-甲磺醯苯氧基)乙基](丙基)胺之醫藥上可接受鹽類的醫藥組成物、及治療帕金森氏症的藥物及所述醫藥組成物的用途
BR112023018771A2 (pt) * 2021-03-17 2023-10-24 Offxet S R L Dispositivo para predizer as condições de desgaste em um paciente afetado pela doença de parkinson
CN112933117B (zh) * 2021-04-28 2023-04-07 遵义医科大学 一种预防和/或治疗帕金森病的药物及其应用
KR20240017910A (ko) * 2021-06-04 2024-02-08 트랜스포손 테라퓨틱스, 인코포레이티드 인지 향상제로서 line-1 억제제
CN113422876B (zh) * 2021-06-24 2022-05-10 广西电网有限责任公司 基于ai的电力客服中心辅助管理方法、系统及介质
US20250134895A1 (en) * 2021-08-16 2025-05-01 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN116832066B (zh) * 2023-08-08 2024-01-12 青岛海洋生物医药研究院股份有限公司 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
AU2007338631A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
EP2658523A1 (en) * 2010-12-28 2013-11-06 Euro-Celtique S.A. A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EP3607943B1 (en) * 2011-04-05 2024-09-11 Grünenthal GmbH Tapentadol for use in treating pain associated with trigeminal neuralgia
US20120277319A1 (en) * 2011-04-29 2012-11-01 Gruenenthal Gmbh Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
BR112015023116A2 (pt) * 2013-03-15 2017-07-18 Melior Discovery Inc composto, composição, formulação para administração oral, método de tratamento de um distúrbio, e, uso de um composto

Also Published As

Publication number Publication date
CN107660147A (zh) 2018-02-02
JP2018515549A (ja) 2018-06-14
JP6853791B2 (ja) 2021-03-31
ES2869981T3 (es) 2021-10-26
AU2016266432B2 (en) 2020-10-22
US20180147160A1 (en) 2018-05-31
US10471025B2 (en) 2019-11-12
EP3302454A1 (en) 2018-04-11
EP3302454B1 (en) 2021-03-10
AU2016266432A1 (en) 2017-11-09
CN107660147B (zh) 2021-04-30
CA2986891C (en) 2022-01-04
WO2016190766A1 (en) 2016-12-01
CA2986891A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
LT3889145T (lt) 8-ciano-5-piperidin-chinolinai, kaip tlr7/8 antagonistai ir jų panaudojimas gydant imuninius sutrikimus
IL277182A (en) Compositions and methods for treating Parkinson's disease
AU2022271491B2 (en) Antisense oligonucleotides for use in treating alzheimer's disease
IL263188B (en) Treatment for Parkinson's disease
ES3064246T3 (en) Compounds for use in methods for treating alzheimer's disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
HUE058749T2 (hu) Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
ZA201807944B (en) Treatment for parkinson's disease
HK40012465A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
GB201504144D0 (en) Treatment of Parkinson's disease